BioNano Genomics Inc (NASDAQ:BNGO) gapped up before the market opened on Friday . The stock had previously closed at $1.04, but opened at $1.07. BioNano Genomics shares last traded at $1.11, with a volume of 2,389,000 shares traded.

Several equities research analysts have weighed in on the company. Zacks Investment Research cut BioNano Genomics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. Maxim Group reissued a “buy” rating and set a $3.00 price objective on shares of BioNano Genomics in a research note on Friday, December 6th.

The stock has a market cap of $28.08 million, a P/E ratio of -0.41 and a beta of 1.57. The business has a 50 day moving average price of $1.12 and a 200 day moving average price of $1.15.

A hedge fund recently raised its stake in BioNano Genomics stock. Virtu Financial LLC grew its holdings in shares of BioNano Genomics Inc (NASDAQ:BNGO) by 204.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 60,904 shares of the company’s stock after buying an additional 40,898 shares during the quarter. Virtu Financial LLC owned 0.23% of BioNano Genomics worth $75,000 at the end of the most recent reporting period. Institutional investors own 3.87% of the company’s stock.

About BioNano Genomics (NASDAQ:BNGO)

Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.

Featured Article: Most Active Stocks: Dollar Volume vs Share Volume

Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.